Abstract
Objectives Chronic Recurrent Multifocal Osteomyelitis (CRMO), also known as chronic nonbacterial osteomyelitis (CNO), is a rare autoinflammatory condition affecting the bones in children and teenagers. The actual incidence of CRMO remains uncertain. The objective of this study is to identify the incidence of CRMO in children and young people under the age of 16 years in the United Kingdom (UK) and Republic of Ireland (ROI). We also aim to delineate the demographics, clinical presentation, investigations, initial management and healthcare needs for children and adolescents with CRMO.
Methods We conducted monthly surveys among all paediatric consultants and paediatric orthopaedic surgeons to identify patients newly diagnosed with CRMO between October 2020 and November 2022. A standardised questionnaire was sent to reporting clinicians to collect further information.
Results Over the surveillance period, 288 patients were reported, among which, 165 confirmed and 20 probable cases were included in the analysis. The highest incidences were among 8-10 year-olds. A two-to-one female-to-male difference in incidence was observed, and male patients were more likely to present with multifocal disease. A negative correlation was observed between reporting clavicular and leg pain. Investigation-wise, 80.0% of patients were reported to have undergone whole-body MRI and 51.1% had bone biopsies. The most common initial treatments were NSAIDs (93.9%) and bisphosphonates (44.8%).
Conclusion This study estimates an average annual CRMO incidence of 0.65 cases per 100,000 children and adolescents in the UK and ROI. These findings establish a crucial baseline for ongoing research and improvement in the care of individuals with CRMO.
Key Messages
The estimated annual incidence of CRMO is 0.65 per 100,000 children and adolescents aged <16.
Two-fold higher incidence in females to males was found, with the highest incidence in 8-10 year-olds.
Male patients are more likely to present with multifocal disease compared with females.
Competing Interest Statement
Athimalaipet Ramanan has received Speaker fees/Honoraria/Consultancy from Abbvie, Eli Lilly, Pfizer, Novartis, SOBI and UCB. Sandrine Compeyrot-Lacassagne has received Consultancy fees from Galapagos/AlfaSigma.
Funding Statement
This work was supported by the British Paediatric Surveillance Unit Sir Peter Tizard Research Bursary and Addenbrookes Charitable Trust. C.S. is supported by an NIHR clinical lectureship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the British Paediatric Surveillance Unit Scientific Committee. Ethical approval was gained from London - Central Research Ethics Committee (reference: 20/LO/0195); Health Research Authority Confidentiality Advisory Group (reference: 20/CAG/0029); Public Benefit and Privacy Panel for Health and Social Care (reference: 1920-0202).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding authors.
